Adocia, a biotech company that specializes in the development of approved protein formulations, has reported positive results for the first clinical trial of its combination insulin formulation of fast- and long-acting insulin in patients with type I diabetes. The formulation, BioChaperone Combo, utilizes Adocia's proprietary technology to solubilize the gold standard basal insulin analog glargine (Lantus, Sanofi) at physiological pH, allowing combination in solution with the rapid-acting insulin analog, lispro (Humalog, Eli Lilly).
The trial evaluated the pharmacodynamics and pharmacokinetics (PK) of BioChaperone Combo compared with a premix formulation of an insulin analog (Humalog Mix, lispro and protamine, Eli Lilly). Results showed that BioChaperone Combo provided both short- and long-term control of blood glucose in type I diabetic patients, with a faster onset and a longer duration of action. Both formulations were well tolerated and did not induce any local reaction.
Tim Heise, medical doctor and CEO of Profil, said in a press release that based on the positive results, single daily injection was possible with BioChaperone Combo and the treatment simplification provided by the combination insulin formulation offers convenience for patients requiring at least two injections per day of premix, or one of Lantus plus at least one of a fast-acting insulin.
The BioChaperone technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and the ease of use for patients. Eight patent applications have been submitted for its combination insulin formulation.